References
Key articles
Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 Mar 29;371(9618):1115-25. Abstract
Brook CA, Schmidt LA. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr Dis Treat. 2008 Feb;4(1):123-43.Full text Abstract
Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011 Dec 20;11:200.Full text Abstract
Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8.Full text Abstract
Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Sys Rev. 2017 Oct 19;(10):CD001206.Full text Abstract
Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Abstract
Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials. Psychol Med. 2008 Jan;38(1):3-14. Abstract
Rowa K, Antony MM. Psychological treatments for social phobia. Can J Psychiatry. 2005 May;50(6):308-16.Full text Abstract
Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Abstract
Roy-Byrne PP, Cowley DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: Nathan P, Gorman JM, eds. A guide to treatments that work. 3rd ed. New York, NY: Oxford University Press; 2007:337-66.
Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Abstract
Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Abstract
National Institute for Health and Care Excellence (UK). Social anxiety disorder: recognition, assessment and treatment. May 2013 [internet publication].Full text
Reference articles
1. Fehm L, Wittchen HU. Comorbidity in social anxiety disorder. In: Bandelow B, Stein DJ, eds. Social anxiety disorder. New York, NY: Marcel Dekker; 2004:49-63.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
3. Poole KL, Cunningham CE, McHolm AE, et al. Distinguishing selective mutism and social anxiety in children: a multi-method study. Eur Child Adolesc Psychiatry. 2021 Jul;30(7):1059-69. Abstract
4. Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005 Nov;66(11):1351-61. Abstract
5. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007 Mar 6;146(5):317-25. Abstract
6. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602.Full text Abstract
7. Hasin DS, Shmulewitz D, Stohl M, et al. Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population. Drug Alcohol Depend. 2015 Jul 1;152:246-56.Full text Abstract
8. Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 Mar 29;371(9618):1115-25. Abstract
9. Cairney J, McCabe L, Veldhuizen S, et al. Epidemiology of social phobia in later life. Am J Geriatr Psychiatry. 2007 Mar;15(3):224-33. Abstract
10. Merikangas KR. Vulnerability factors for anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2005 Oct;14(4):649-79;vii. Abstract
11. Stein DJ, Lim CCW, Roest AM, et al. The cross-national epidemiology of social anxiety disorder: data from the World Mental Health Survey Initiative. BMC Med. 2017 Jul 31;15(1):143.Full text Abstract
12. Carter MM, Mitchell FE, Sbrocco T. Treating ethnic minority adults with anxiety disorders: current status and future recommendations. J Anxiety Disord. 2012 May;26(4):488-501.Full text Abstract
13. Brook CA, Schmidt LA. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr Dis Treat. 2008 Feb;4(1):123-43.Full text Abstract
14. Spence SH, Rapee RM. The etiology of social anxiety disorder: an evidence-based model. Behav Res Ther. 2016 Nov;86:50-67. Abstract
15. Stein MB, Gelernter J, Smoller JW. Genetic aspects of social anxiety and related traits. In: Brandelow B, Stein DJ, eds. Social anxiety disorder. New York, NY: Marcel Dekker; 2004:197-214.
16. Barlow DH. Anxiety and its disorders, 2nd ed. New York, NY: Guilford Press; 2002.
17. Stein MB, Chen CY, Jain S, et al. Genetic risk variants for social anxiety. Am J Med Genet B Neuropsychiatr Genet. 2017 Mar;174(2):120-31.Full text Abstract
18. Hirshfeld-Becker DR, Biederman J, Henin A, et al. Behavioral inhibition in preschool children at risk is a specific predictor of middle childhood social anxiety: a five-year follow-up. J Dev Behav Pediatr. 2007 Jun;28(3):225-33. Abstract
19. Xu J, Ni S, Ran M, et al. The relationship between parenting styles and adolescents' social anxiety in migrant families: a study in Guangdong, China. Front Psychol. 2017;8:626.Full text Abstract
20. Plasencia ML, Alden LE, Taylor CT. Differential effects of safety behaviour subtypes in social anxiety disorder. Behav Res Ther. 2011 Oct;49(10):665-75. Abstract
21. Piccirillo ML, Taylor Dryman M, Heimberg RG. Safety behaviors in adults with social anxiety: review and future directions. Behav Ther. 2016 Sep;47(5):675-87. Abstract
22. Roth DA, Heimberg RG. Cognitive behavioral models of social anxiety disorder. Psychiatr Clin North Am. 2001 Dec;24(4):753-71. Abstract
23. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476-1488.Full text Abstract
24. Freitas-Ferrari MC, Hallak JE, Trzesniak C, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:565-580. Abstract
25. Schwartz CE, Wright CI, Shin LM, et al. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science. 2003;300:1952-1953. Abstract
26. Condren RM, O'Neill A, Ryan MC, et al. HPA axis response to a psychological stressor in generalised social phobia. Psychoneuroendocrinology. 2002;27:693-703. Abstract
27. van West D, Claes S, Sulon J, et al. Hypothalamic-pituitary-adrenal reactivity in prepubertal children with social phobia. J Affect Disord. 2008;111:281-290. Abstract
28. Gelernter J, Page GP, Stein MB, et al. Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus. Am J Psychiatry. 2004;161:59-66. Abstract
29. Doehrmann O, Ghosh SS, Polli FE, et al. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013;70:87-97. Abstract
30. Hirshfeld-Becker DR, Micco JA, Simoes NA, et al. High risk studies and developmental antecedents of social anxiety disorder. Am J Med Genet. 2008 May 15;148C(2):99-117. Abstract
31. Aune T, Stiles TC. Universal-based prevention of syndromal and subsyndromal social anxiety: a randomized controlled study. J Consult Clin Psychol. 2009 Oct;77(5):867-79. Abstract
32. Jefferson JW. Social phobia: a pharmacologic treatment overview. J Clin Psychiatry. 1995;56(suppl 5):18-24. Abstract
33. Muller U, Mottweiler E, Bublak P. Noradrenergic blockade and numeric working memory in humans. J Psychopharmacol. 2005 Jan;19(1):21-8. Abstract
34. Liebowitz, MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992 Apr;49(4):290-300. Abstract
35. Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994 Apr;62(2):350-8. Abstract
36. Falloon IR, Lloyd GG, Harpin RE. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis. 1981 Mar;169(3):180-4. Abstract
37. Stein MB, Sareen J, Hami S, et al. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001 Oct;158(10):1725-7. Abstract
38. Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. 2016 Feb;30(2):128-39.Full text Abstract
39. Wang PS, Berglund P, Olfson M, et al. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):603-13.Full text Abstract
40. Wagner R, Silove D, Marnane C, et al. Delays in referral of patients with social phobia, panic disorder, and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord. 2006;20(3):363-71. Abstract
41. Taylor CT, Laposa JM, Alden LE. Is avoidant personality disorder more than just social avoidance? J Pers Disord. 2004 Dec;18(6):571-94. Abstract
42. Cox BJ, Pagura J, Stein MB, et al. The relationship between generalized social phobia and avoidant personality disorder in a national mental health survey. Depress Anxiety. 2009;26(4):354-62. Abstract
43. Heimberg RG. Social phobia, avoidant personality disorder, and the multiaxial conceptualization of interpersonal anxiety. In: Salkovskis PM, ed. Trends in cognitive and behavioural therapies. Chichester: Wiley; 1996:43-61.
44. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.Full text Abstract
45. Mennin DS, Fresco DM, Heimberg RG, et al. Screening for social anxiety disorder in the clinical setting: the Liebowitz Social Anxiety Scale. J Anxiety Disord. 2002;16(6):661-73. Abstract
46. Connor K, Kobak KA, Churchill E, et al. Mini-SPIN: a brief screening assessment for generalized social anxiety disorder. Depress Anxiety. 2001;14(2):137-40. Abstract
47. US Preventive Services Task Force. Anxiety in children and adolescents: screening. Oct 2022 [internet publication].Full text
48. Gregory KD, Chelmow D, Nelson HD, et al. Screening for anxiety in adolescent and adult women: a recommendation from the Women's Preventive Services Initiative. Ann Intern Med. 2020 Jul 7;173(1):48-56. Abstract
49. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.Full text Abstract
50. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. Abstract
51. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003 Aug 1;1:29.Full text Abstract
52. Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1107-24.Full text Abstract
53. British Columbia Medical Association Guidelines & Protocols Advisory Committee. Anxiety and depression in children and youth: diagnosis and treatment. January 2010 [internet publication].Full text
54. National Institute for Health and Care Excellence (UK). Social anxiety disorder: recognition, assessment and treatment. May 2013 [internet publication].Full text
55. Andrews G, Bell C, Boyce P, et al. Clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Royal Australian and New Zealand College of Psychiatrists. 2018;52(12):1109-72.Full text
56. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203-15.Full text Abstract
57. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(suppl 12):20-6. Abstract
58. Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1.Full text Abstract
59. Bandelow B, Seidler-Brandler U, Becker A, et al. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007;8(3):175-87. Abstract
60. James AC, Reardon T, Soler A, et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2020 Nov 16;(11):CD013162. Abstract
61. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008 Dec 25;359(26):2753-66.Full text Abstract
62. Ginsburg GS, Kendall PC, Sakolsky D, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011 Dec;79(6):806-13.Full text Abstract
63. Wang Z, Whiteside SPH, Sim L, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. JAMA Pediatr. 2017 Nov 1;171(11):1049-56.Full text Abstract
64. Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-32.Full text Abstract
65. Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006 Jan;26(1):17-31. Abstract
66. Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials. Psychol Med. 2008 Jan;38(1):3-14. Abstract
67. Rowa K, Antony MM. Psychological treatments for social phobia. Can J Psychiatry. 2005 May;50(6):308-16.Full text Abstract
68. Beidel DC, Ferrell C, Alfano CA, et al. The treatment of childhood social anxiety disorder. Psychiatr Clin North Am. 2001 Dec;24(4):831-46. Abstract
69. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001 Jun;21(3):311-24. Abstract
70. Acarturk C, Cuijpers P, van Straten A, et al. Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009 Feb;39(2):241-54. Abstract
71. Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014 Oct;1(5):368-76.Full text Abstract
72. Aderka IM. Factors affecting treatment efficacy in social phobia: the use of video feedback and individual vs. group formats. J Anxiety Disord. 2009 Jan;23(1):12-7. Abstract
73. Hedman E, Ljótsson B, Lindefors N. Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):745-64. Abstract
74. Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. J Anxiety Disord. 2018 Apr;55:70-8.Full text Abstract
75. Dear BF, Staples LG, Terides MD, et al. Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for social anxiety disorder and comorbid disorders: a randomized controlled trial. J Anxiety Disord. 2016 Aug;42:30-44.Full text Abstract
76. Hedman E, Andersson G, Ljotsson B, et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS One. 2011 Mar 25;6(3):e18001.Full text Abstract
77. Hedman E, Furmark T, Carlbring P, et al. A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res. 2011 Jun 15;13(2):e39.Full text Abstract
78. Olthuis JV, Watt MC, Bailey K, et al. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016;(3):CD011565.Full text Abstract
79. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001 Jun;21(3):311-24. Abstract
80. Bandelow B, Sagebiel A, Belz M, et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018 Jun;212(6):333-8.Full text Abstract
81. Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011 Dec 20;11:200.Full text Abstract
82. Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8.Full text Abstract
83. Craske MG, Stein MB, Sullivan G, et al. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry. 2011 Apr;68(4):378-88.Full text Abstract
84. Clark DM. Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: the IAPT experience. Int Rev Psychiatry. 2011 Aug;23(4):318-27.Full text Abstract
85. Gyani A, Shafran R, Layard R, et al. Enhancing recovery rates: lessons from year one of IAPT. Behav Res Ther. 2013 Sep;51(9):597-606.Full text Abstract
86. Wakefield S, Kellett S, Simmonds-Buckley M, et al. Improving Access to Psychological Therapies (IAPT) in the United Kingdom: a systematic review and meta-analysis of 10-years of practice-based evidence. Br J Clin Psychol. 2021 Mar;60(1):1-37.Full text Abstract
87. Baigent M, Smith D, Battersby M, et al. The Australian version of IAPT: clinical outcomes of the multi-site cohort study of NewAccess. J Ment Health. 2020 May 12;1-10. Abstract
88. Knapstad M, Smith ORF. Social anxiety and agoraphobia symptoms effectively treated by Prompt Mental Health Care versus TAU at 6- and 12-month follow-up: secondary analysis from a randomized controlled trial. Depress Anxiety. 2021 Mar;38(3):351-60.Full text Abstract
89. Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Sys Rev. 2017 Oct 19;(10):CD001206.Full text Abstract
90. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep. 2010 Oct;12(5):471-7. Abstract
91. Roy-Byrne PP, Veitengruber JP, Bystritsky A, et al. Brief intervention for primary care anxiety: a medication focused approach. J Am Board Fam Med. 2009 Mar-Apr;22(2):175-86.Full text Abstract
92. de Menezes GB, Coutinho ES, Fontenelle LF, et al. Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials. Psychopharmacology (Berl). 2011 May;215(1):1-11. Abstract
93. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29-40. Abstract
94. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Abstract
95. Roy-Byrne PP, Cowley DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: Nathan P, Gorman JM, eds. A guide to treatments that work. 3rd ed. New York, NY: Oxford University Press; 2007:337-66.
96. Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002 Jun;22(3):257-62. Abstract
97. Liebowitz MB, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005 Feb;62(2):190-8.Full text Abstract
98. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002 Feb;63(2):152-5. Abstract
99. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014 May;28(5):403-39. Abstract
100. Stein DJ, Versiani M, Hair T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002 Dec;59(12):1111-8.Full text Abstract
101. Montgomery SA, Nil R, Durr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005 Oct;66(10):1270-8. Abstract
102. Walker JR, van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000 Dec;20(6):636-44. Abstract
103. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017 Sep 25;358:j4461.Full text Abstract
104. Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992 Apr;49(4):282-8. Abstract
105. Kessler KC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998 May;155(5):613-9.Full text Abstract
106. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013 Jan;28(1):7-20. Abstract
107. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993 Dec;13(6):423-8. Abstract
108. Otto MW, Pollack MH, Gould RA, et al. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000 Jul-Aug;14(4):345-58. Abstract
109. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004 Feb;65(2):244-8. Abstract
110. Davidson JR, Tupler LA, Potts NL. Treatment of social phobia with benzodiazepines. J Clin Psychiatry. 1994 Jun;(suppl 55):28-32. Abstract
111. Kennedy KM, O'Riordan J. Prescribing benzodiazepines in general practice. Br J Gen Pract. 2019 Mar;69(680):152-3.Full text Abstract
112. Liebowitz, MR, Fyer AJ, Gorman JM, et al. Phenelzine in social phobia. J Clin Psychopharmacol. 1986 Apr;6(2):93-8. Abstract
113. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997;247(2):71-80. Abstract
114. Noyes R, Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug;17(4):247-54. Abstract
115. Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998 Jan;172:70-7. Abstract
116. Atmaca M, Kuloglu M, Tezcan E, et al. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5. Abstract
117. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1995 Nov;92(5):351-8. Abstract
118. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol. 1997 Aug;17(4):255-60. Abstract
119. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999 Aug;19(4):341-8. Abstract
120. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 Apr;24(2):141-9. Abstract
121. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 Jan;29(1):26-48. Abstract
122. Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011 Jul;26(4):213-20. Abstract
123. Greist JH, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011 Sep;26(5):243-51. Abstract
124. Beaumont G. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res. 1977;5(suppl 5):116-23. Abstract
125. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998 Apr;18(2):132-5. Abstract
126. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005 Dec;25(6):580-3. Abstract
127. Davis ML, Smits JA, Hofmann SG. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opin Pharmacother. 2014 Nov;15(16):2281-91. Abstract
128. Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Abstract
129. Feldman G. Cognitive and behavioral therapies for depression: overview, new directions, and practical recommendations for dissemination. Psychiatr Clin North Am. 2007 Mar;30(1):39-50. Abstract
130. Ott CA. Treatment of anxiety disorders in patients with comorbid bipolar disorder. Ment Health Clin. 2018 Nov;8(6):256-63.Full text Abstract
131. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1:91-111. Abstract
132. Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials. Psychol Med. 2008 Jan;38(1):3-14. Abstract
133. Rowa K, Antony MM. Psychological treatments for social phobia. Can J Psychiatry. 2005 May;50(6):308-16.Full text Abstract
134. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Abstract
135. Roy-Byrne PP, Cowley DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: Nathan P, Gorman JM, eds. A guide to treatments that work. 3rd ed. New York, NY: Oxford University Press; 2007:337-66.
136. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Abstract
137. Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan;171(1):44-53. Abstract
138. Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Abstract
139. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203-15.Full text Abstract
140. National Institute for Health and Care Excellence (UK). Social anxiety disorder: recognition, assessment and treatment. May 2013 [internet publication].Full text
141. Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002 Dec;16(4):365-8. Abstract
142. Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry. 2005 Apr;66(4):540-2. Abstract
143. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008120.Full text Abstract
144. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996 Jul 8;39(2):115-21. Abstract
145. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008 Mar 15;63(6):544-9. Abstract
146. Hofmann SG, Smits JA, Rosenfield D, et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013 Jul;170(7):751-8.Full text Abstract
147. Lipsitz JD, Gur M, Vermes D, et al. A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety. 2008;25(6):542-53. Abstract
148. Amir N, Bomyea J, Beard C. The effect of single-session interpretation modification on attention bias in socially anxious individuals. J Anxiety Disord. 2010 Mar;24(2):178-82.Full text Abstract
149. Klinger E, Bouchard S, Legeron P, et al. Virtual reality therapy versus cognitive behavioral therapy for social phobia: a preliminary controlled study. Cyberpsychol Behav. 2005 Feb;8(1):76-88. Abstract
150. Dear BF, Staples LG, Terides MD, et al. Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for social anxiety disorder and comorbid disorders: a randomized controlled trial. J Anxiety Disord. 2016 Aug;42:30-44.Full text Abstract
151. Norton PJ, Barrera TL. Transdiagnostic versus diagnosis-specific CBT for anxiety disorders: a preliminary randomized controlled noninferiority trial. Depress Anxiety. 2012 Oct;29(10):874-82.Full text Abstract
152. Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. Br J Sports Med. 2014 Feb;48(3):187-96. Abstract
153. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84. Abstract
154. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008;9(4):248-312.Full text Abstract
155. National Institute for Health and Care Excellence (UK). Computerised cognitive behaviour therapy for depression and anxiety. 22 February 2006 [internet publication].Full text
156. Haug T, Blomhoff S, Hellstrom K, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003 Apr;182:312-8.Full text Abstract
157. US Food and Drug Administration. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. May 2007 [internet publication].
159. Reisman Y. Sexual Consequences of post-SSRI syndrome. Sex Med Rev. 2017 Oct;5(4):429-33. Abstract
160. Stein DJ, Versiani M, Hair T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002 Dec;59(12):1111-8.Full text Abstract
161. Montgomery SA, Nil R, Durr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005 Oct;66(10):1270-8. Abstract
162. Walker JR, van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000 Dec;20(6):636-44. Abstract
163. Krause KR, Chung S, Adewuya AO, et al. International consensus on a standard set of outcome measures for child and youth anxiety, depression, obsessive-compulsive disorder, and post-traumatic stress disorder. Lancet Psychiatry. 2021 Jan;8(1):76-86. Abstract
Use of this content is subject to our disclaimer